Merial Limited v Intervet International B.V

Link copied
Case Copied 14 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Merial Limited v Intervet International B.V. [2018] APO 25

Patent Application:                2006289102

Title:PCV-2 vaccine

Patent Applicant:                   Intervet International B.V.

Opponent:  Merial Limited

Delegate:  Dr B. Akhurst

Decision Date:  3 April 2018

Hearing Date:  Written submissions filed on 31 January 2018, 14 February 2018 and 21 February 2018.

Catchwords:  PATENTS – Final determination – the amendment overcomes the ground of opposition and does not introduce new deficiencies – application to proceed to grant.

Representation:  Patent attorney for the applicant:  Spruson and Ferguson.

Patent attorney for the opponent:  FB Rice.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2006289102

Title:PCV-2 vaccine

Patent Applicant:                   Intervet International B.V.

Date of Decision:                   3 April 2018

DECISION

The amendments to the specification overcome the deficiencies identified in the first decision in this s 59 opposition and do not introduce new deficiencies.

Subject to an appeal of this decision, I direct the application proceed to grant.

Costs according to Schedule 8 are awarded against Merial Limited.

REASONS FOR DECISION

Background

  1. Patent application 2006289102 was filed by Intervet International B.V. (Intervet) on 8 September 2006, claiming the priority date 9 September 2005.  Acceptance of the application was advertised on 15 December 2011.

  2. Merial Limited (Merial) opposed the grant of a patent under s 59 of the Patents Act 1990 (the Act).  The matter was heard, and in the decision published on 27 June 2016 as Merial Limited v Intervet International B.V. [2016] APO 39 (the first decision), certain claims of the specification were found to lack an inventive step.  As is usual in such matters before the Commissioner, Intervet was allowed a period of time to propose amendments to the claims to overcome this deficiency.  Intervet did so, and the grant of leave to amend was advertised on 5 January 2017.  Merial’s opposition under s 104(4) to allowance of the amendments was unsuccessful - this decision was published on 19 September 2017 as Merial Limited v Intervet International [2017] APO 47 (the amendments decision).  Allowance of the amendment request was published on 30 November 2017.   

  3. Merial asked to be heard before the s 59 opposition was finally determined and the hearing took place by way of written submissions in filed on 31 January 2018, 14 February 2018 and 21 February 2018.

    The first hearing and decision

  4. The accepted specification contained 12 claims.  Most relevant to this current matter, accepted claim 12 is an ‘omnibus’ claim, limiting the subject matter of each one of the earlier claims to being “substantially as herein described with reference to any one of the examples”. 

  5. Merial’s grounds of opposition to the accepted specification are identified in the amended Statement of Grounds and Particulars dated 23 March 2015 as follows:

    · the applicant is not entitled to the invention contrary to s 59(a); and

    · the claimed invention is not patentable under section 59(b) because it does not comply with the requirements of:

    ·     section 18 with respect to manner…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merial Limited v Intervet International B.V and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] APO 25
Decision Date

CaseChat Overview and Summary

The matter before the court was an opposition to the grant of a patent for a PCV-2 vaccine by Merial Limited against Intervet International B.V. The court had to decide whether the amended claims of the patent application met the requirements of the Patents Act 1990 and whether the opposition should be dismissed. The central legal issues were whether the amended claims involved an inventive step, if the specification fully described the invention, and if the omnibus clause rendered the claims unclear. The court found that the amendments overcame the deficiencies identified in the earlier decision and did not introduce new deficiencies. The opposition was dismissed, and costs were awarded against Merial Limited.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.